Diagnostic and Therapeutic Implications of Sortilin Expressed on the Surface of Bladder Carcinoma Cells
Publish place: IRANIAN JOURNAL of PATHOLOGY، Vol: 17، Issue: 2
Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 256
This Paper With 9 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IJP-17-2_008
تاریخ نمایه سازی: 18 فروردین 1401
Abstract:
Background & Objective: Cell surface expression of sortilin in different types of cancer signifies it as a therapeutic target for cancer therapy. The aim of this study was to detect sortilin expression in bladder cancer cells using an anti-sortilin monoclonal antibody (mAb) to evaluate sortilin as a target for developing diagnostic and therapeutic agents against bladder carcinoma.Methods: The protein expression of sortilin in bladder cancer tissues and cell lines (۵۶۳۷ and EJ۱۳۸) was investigated by immunohistochemistry (IHC), immune-cytochemistry (ICC), and flow cytometry. Furthermore, the capability of anti-sortilin mAb in apoptosis induction in bladder cancer cells was evaluated.Results: A high expression level was observed in bladder carcinoma tissues (P≤۰.۰۰۱) and cell lines, using IHC and ICC, respectively. Flow cytometry results showed cell surface expression of ۲۷.۵±۳% (P≤۰.۰۱), ۷۴.۴±۷.۸% (P≤۰.۰۰۱), and ۴.۲±۰.۴% of sortilin in EJ۱۳۸, ۵۶۳۷, and HFFF cells, respectively. In EJ۱۳۸ anti-sortilin mAb induced apoptosis in ۲۵.۲±۱۱.۵% (P≤۰.۰۵) (early) and ۴.۵±۱.۱% (P>۰.۰۵) (late) after ۶ h incubation, while for ۱۲ h, the values of ۱۱.۶±۳.۸% (P>۰.۰۵) and ۲۰.۷±۴.۴% (P≤۰.۰۵) were achieved. In ۵۶۳۷ cells, ۶ h incubation resulted in ۱۰.۲±۰.۳% (P>۰.۰۵) and ۶.۶±۱.۴% (P>۰.۰۵) apoptosis induction, while these values were ۱۲.۱±۰.۸% (P>۰.۰۵) and ۲۷.۴±۴.۵% (P≤۰.۰۱) after ۱۲ h. The HFFF cells did not show significant apoptosis.Conclusion: The overexpression of sortilin in bladder tumor cells and its potential in inducing apoptosis via directed targeting with the specific monoclonal antibody may represent this protein as a potential candidate of targeted therapy in bladder carcinoma.
Keywords:
Authors
Bayat Ali-Ahmad
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Sadeghi Niloufar
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Fazli Ghazaleh
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Nowroozi Mohammad Reza
Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Ohadian Moghadam Solmaz
Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Radmanesh Amin
Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :